Matches in SemOpenAlex for { <https://semopenalex.org/work/W2340407924> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2340407924 endingPage "A151" @default.
- W2340407924 startingPage "A151.1" @default.
- W2340407924 abstract "<h3>Background</h3> A reduction in the risk of asthma exacerbation may provide improvements in clinical burden, patient experience and healthcare costs. In Phase III trials, once-daily tiotropium Respimat® add-on to at least ICS improved lung function in patients with symptomatic asthma. We investigated exacerbation risk in each trial. <h3>Methods</h3> Five Phase III, double-blind, placebo-controlled, parallel-group trials in patients with symptomatic asthma. Patients received tiotropium Respimat® 5 µg or placebo Respimat® each as add-on to at least ICS maintenance therapy (Table 1). Pre-planned co-primary or secondary end points were time to first severe exacerbation and time to any asthma worsening. <h3>Results</h3> Mean baseline% of predicted FEV<sub>1</sub>, ACQ-7 score and ICS dose (µg) were: 56.0 ± 13.1, 2.6 ± 0.7 and 1198 ± 539 in PrimoTinA-asthma® (two replicate trials); 75.1 ± 11.5, 2.2 ± 0.5 and 660 ± 213 in MezzoTinA-asthma® (two replicate trials); and 77.7 ± 11.9, 2.1 ± 0.4 and 381 ± 78 in GraziaTinA-asthma®. Tiotropium Respimat® 5 µg reduced risk of severe asthma exacerbation by at least 21% in all three severity cohorts (Table 1) and risk of asthma worsening versus placebo Respimat® in all trials, with a statistically significant reduction in PrimoTinA-asthma®. <h3>Conclusion</h3> Once-daily tiotropium Respimat® 5 µg add-on to at least ICS maintenance therapy consistently reduced exacerbations across asthma severities and so may be a beneficial add-on option to reduce current and future exacerbation risk." @default.
- W2340407924 created "2016-06-24" @default.
- W2340407924 creator A5013428765 @default.
- W2340407924 creator A5022845882 @default.
- W2340407924 creator A5037297396 @default.
- W2340407924 creator A5038228413 @default.
- W2340407924 creator A5044586131 @default.
- W2340407924 creator A5064790505 @default.
- W2340407924 creator A5079069521 @default.
- W2340407924 creator A5085341243 @default.
- W2340407924 date "2015-11-12" @default.
- W2340407924 modified "2023-09-26" @default.
- W2340407924 title "P148 Once-daily tiotropium Respimat® add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma: Abstract P148 Table 1" @default.
- W2340407924 doi "https://doi.org/10.1136/thoraxjnl-2015-207770.285" @default.
- W2340407924 hasPublicationYear "2015" @default.
- W2340407924 type Work @default.
- W2340407924 sameAs 2340407924 @default.
- W2340407924 citedByCount "0" @default.
- W2340407924 crossrefType "journal-article" @default.
- W2340407924 hasAuthorship W2340407924A5013428765 @default.
- W2340407924 hasAuthorship W2340407924A5022845882 @default.
- W2340407924 hasAuthorship W2340407924A5037297396 @default.
- W2340407924 hasAuthorship W2340407924A5038228413 @default.
- W2340407924 hasAuthorship W2340407924A5044586131 @default.
- W2340407924 hasAuthorship W2340407924A5064790505 @default.
- W2340407924 hasAuthorship W2340407924A5079069521 @default.
- W2340407924 hasAuthorship W2340407924A5085341243 @default.
- W2340407924 hasBestOaLocation W23404079241 @default.
- W2340407924 hasConcept C126322002 @default.
- W2340407924 hasConcept C142724271 @default.
- W2340407924 hasConcept C168563851 @default.
- W2340407924 hasConcept C177713679 @default.
- W2340407924 hasConcept C1862650 @default.
- W2340407924 hasConcept C204787440 @default.
- W2340407924 hasConcept C27081682 @default.
- W2340407924 hasConcept C2776042228 @default.
- W2340407924 hasConcept C2776694085 @default.
- W2340407924 hasConcept C2776780178 @default.
- W2340407924 hasConcept C2777014857 @default.
- W2340407924 hasConcept C2778283404 @default.
- W2340407924 hasConcept C2909082789 @default.
- W2340407924 hasConcept C535046627 @default.
- W2340407924 hasConcept C71924100 @default.
- W2340407924 hasConceptScore W2340407924C126322002 @default.
- W2340407924 hasConceptScore W2340407924C142724271 @default.
- W2340407924 hasConceptScore W2340407924C168563851 @default.
- W2340407924 hasConceptScore W2340407924C177713679 @default.
- W2340407924 hasConceptScore W2340407924C1862650 @default.
- W2340407924 hasConceptScore W2340407924C204787440 @default.
- W2340407924 hasConceptScore W2340407924C27081682 @default.
- W2340407924 hasConceptScore W2340407924C2776042228 @default.
- W2340407924 hasConceptScore W2340407924C2776694085 @default.
- W2340407924 hasConceptScore W2340407924C2776780178 @default.
- W2340407924 hasConceptScore W2340407924C2777014857 @default.
- W2340407924 hasConceptScore W2340407924C2778283404 @default.
- W2340407924 hasConceptScore W2340407924C2909082789 @default.
- W2340407924 hasConceptScore W2340407924C535046627 @default.
- W2340407924 hasConceptScore W2340407924C71924100 @default.
- W2340407924 hasIssue "Suppl 3" @default.
- W2340407924 hasLocation W23404079241 @default.
- W2340407924 hasOpenAccess W2340407924 @default.
- W2340407924 hasPrimaryLocation W23404079241 @default.
- W2340407924 hasRelatedWork W1957770986 @default.
- W2340407924 hasRelatedWork W2044533615 @default.
- W2340407924 hasRelatedWork W2104609688 @default.
- W2340407924 hasRelatedWork W2271454365 @default.
- W2340407924 hasRelatedWork W2312981776 @default.
- W2340407924 hasRelatedWork W2340407924 @default.
- W2340407924 hasRelatedWork W2607349441 @default.
- W2340407924 hasRelatedWork W2991348257 @default.
- W2340407924 hasRelatedWork W3032454103 @default.
- W2340407924 hasRelatedWork W4225925351 @default.
- W2340407924 hasVolume "70" @default.
- W2340407924 isParatext "false" @default.
- W2340407924 isRetracted "false" @default.
- W2340407924 magId "2340407924" @default.
- W2340407924 workType "article" @default.